The Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among Black men with early-stage disease, according to results presented at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting in Washington, DC. The study conclusions, which were drawn from the prospective VANDAAM trial, confirm that the genomic test offers physicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions for Black men, a population that is disproportionately impacted by the disease, according to a statement issued by the makers of the test, Veracyte, Inc.1
The VANDAAM trial enrolled men with low- or intermediate-risk prostate cancer as classified by the National Comprehensive Cancer Network Guidelines for Prostate Cancer. Researchers evaluated data for 113 Black men and 113 non-Black men and performed genomic analysis using the Decipher Prostate classifier to generate Decipher risk scores.
Following standard treatment, patients with high Decipher test scores were 8 times more likely to have biochemical recurrence within 2 years, compared with those with lower genomic test scores.
“The Decipher Prostate test’s ability to accurately predict risk of a patient’s prostate cancer progressing has already been demonstrated in dozens of clinical studies,” Elai Davicioni, PhD, Veracyte’s medical director for urology noted in a statement about the results. “While prior retrospective data showed that Decipher is highly prognostic in African Americans, these patients have historically been under-represented in biomarker clinical studies. We applaud the VANDAAM study team for conducting the first prospective clinical trial to examine the effectiveness of genomic risk-stratification in African American men—results that could potentially help to narrow the prostate cancer disparity gap.”1
Reference
- New data presented at ASTRO 2024 show that Veracyte’s Decipher Prostate test predicts aggressive prostate cancer in African American men. Press release. Veracyte. October 2, 2024. Accessed October 18, 2024. https://investor.veracyte.com/news-releases/news-release-details/new-data-presented-astro-2024-show-veracytes-decipher-prostate